Latest TMO news and sentiment

This story was originally published on Trucking Dive. To receive daily news and insights, subscribe to our free daily Trucking Dive newsletter. XPO appointed Jonas Svedlund chief legal officer, according to an Aug. 10 press release. Svedlund, whose appointment was effective immediately, most recently was deputy general counsel for Thermo Fisher Scientific, where he oversaw the company's corporate and commercial legal functions, per the release. He also held executive roles with General Electric, including time as general counsel for two separate GE businesses. Mario Harik, chairman and CEO of

Published

21 Aug 2026 11:15

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Published

17 Aug 2026 04:16

Provider record

google_news

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Envetec Senior Thermo Fisher Scientific executive brings nearly 30 years of healthcare and commercial leadership to support Envetec's global expansion Patrick S. JonesPatrick S. Jones, President of Thermo Fisher Scientific's Clinical Diagnostics Division and independent director of Envetec Sustainable Technologies BIRDHILL, Ireland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Envetec Sustainable Technologies Limited (Envetec), a leading sustainability innovator in clean technology for healthcare and life sciences, today announced the appointment of Patrick S. Jones, president of Thermo Fisher Scientific

Published

14 Aug 2026 08:00

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

LivaNova PLC recently reported second-quarter 2026 results showing sales rising to US$390.59 million and net income climbing to US$108.57 million, alongside higher earnings per share versus a year earlier. On the back of this performance, the company raised its 2026 constant-currency revenue growth guidance to a range of 8% to 9% and secured a long-term oxygenator supply agreement with Thermo Fisher Scientific to support manufacturing expansion. Now we'll examine how the raised 2026 growth outlook and manufacturing investments may influence LivaNova's existing investment narrative. Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. LivaNova Investment Narrative Recap To own LivaNova, you need to believe its cardiopulmonary and neuromodulation franchises can keep converting procedure demand into profitable, recurring revenue while managing pricing and reimbursement pressure. The Q2 2026 beat and higher revenue outlook support the near term growth catalyst in cardiopulmonary, but also highlight the key risk that higher manufacturing and IT spending, if not carefully controlled, could squeeze margins even as volumes rise. The long term oxygenator supply agreement with Thermo Fisher Scientific is especially relevant here, because it directly addresses prior supply constraints in cardiopulmonary consumables. By securing critical components and supporting capacity expansion, LivaNova is trying to align its manufacturing footprint with the heightened 2026 guidance, which may help underpin the cardiopulmonary growth story while leaving execution and supplier dependence as issues to watch. Yet even with stronger guidance, investors should be aware that higher spending on capacity and IT could still pressure margins if... Read the full narrative on LivaNova (it's free!) LivaNova's narrative projects $1.8 billion revenue and $220.8 million earnings by 2029. Uncover how LivaNova's forecasts yield a $84.80 fair value, a 5% upside to its current price. Exploring Other PerspectivesLIVN 1-Year Stock Price Chart Some of the lowest ranked analysts were assuming only about 5 percent annual revenue growth and US$177.7 million in earnings by 2029, so compared with today's stronger guidance and supply agreement, their view reflects a far more cautious stance on supplier bottlenecks and margin pressure that you may want to compare with your own expectations. Explore 2 other fair value estimates on LivaNova - why the stock might be worth just $84.80! Story Continues The Verdict Is Yours Don't just follow the ticker - dig into the data and build a conviction that's truly your own. A great starting point for your LivaNova research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision. Our free LivaNova research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate LivaNova's overall financial health at a glance. No Opportunity In LivaNova? These stocks are moving-our analysis flagged them today. Act fast before the price catches up: Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution. The future of work is here. Discover the 39 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. Outshine the giants: these 16 early-stage AI stocks could fund your retirement. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven

Published

13 Aug 2026 00:16

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. LivaNova (LIVN) raised its full year 2026 revenue and earnings guidance after reporting record quarterly revenue and significantly higher profitability, supported by demand for its Essenz heart-lung machine and a new supply agreement with Thermo Fisher Scientific. See our latest analysis for LivaNova. LivaNova's recent guidance lift comes after a strong run in the share price, with a 90 day share price return of 12.71% and a year to date share price return of 33.21%. The 1 year total shareholder return of 52.24% suggests momentum has been building over a longer stretch. If you are looking for more ideas in healthcare technology, this is a good moment to widen the search with 43 healthcare AI stocks Bulls argue that LivaNova's guidance lift and profitability reset justify a rerating. Bears see a hot chart and guidance upgrade as already reflected in the price. Do current valuation markers support the optimism or the caution? Most Popular Narrative: 4.7% Undervalued LivaNova's most followed narrative sets a fair value of $84.80 against the last close at $80.78, which points to a modest valuation gap that hinges on how durable its cardiopulmonary and neuromodulation growth proves to be over time. The company's clinical innovations, including strong, durable VNS study data in epilepsy and depression, the launch of disruptive next-generation OSA neurostimulation (p-HGNS), and continued product upgrades (such as the Essenz platform's software upgradability), position LivaNova to capture share from the long-term shift toward minimally invasive, personalized therapies, which can drive pricing power and higher net margins. Read the complete narrative. Want to see what sits behind that confidence in LivaNova's therapies? The fair value leans on steady top line progress, margin uplift and a richer earnings mix. Curious which specific revenue path and profitability targets underpin that 4.7% gap? The full narrative lays out the concrete milestones that have to fall into place. Result: Fair Value of $84.80 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, LivaNova's story can change quickly if reimbursement tightens or if key neuromodulation and sleep apnea launches face regulatory or adoption setbacks. Find out about the key risks to this LivaNova narrative. Next Steps Story Continues With LivaNova pulling in both optimism and concern, it makes sense to check the underlying data yourself and move quickly to form your own stance by weighing its 4 key rewards and 1 important warning sign Looking for more investment ideas beyond LivaNova? If you want a broader watchlist alongside LivaNova, use the Simply Wall Street Screener to quickly spot other stocks that might fit your style and goals. Target potential bargains early by scanning the 49 high quality undervalued stocks to see which stocks currently trade below their assessed value. Focus on resilience by reviewing the 84 resilient stocks with low risk scores so you can concentrate on companies with lower overall risk scores. Get ahead of the crowd by checking the screener containing 20 high quality undiscovered gems to see which under-the-radar stocks have strong fundamentals before others catch on. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in

Published

12 Aug 2026 23:09

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

The transaction establishes an independent company, with the Microbiology business providing the foundation of a global microbiology diagnostics platform serving the clinical, food safety and pharmaceutical markets. The investment reflects Astorg's focused healthcare strategy and distinctive approach to complex transactions, combining deep sector expertise, and a strong track record of operational value creation. Dirk Bontridder has been appointed Chief Executive Officer to lead the company through its next stage of growth, in partnership with Astorg. LUXEMBOURG & NEW YORK & PARIS, August 12, 2026--(BUSINESS WIRE)--Astorg, a leading pan-European private equity firm, today announced the successful completion of its acquisition of the global microbiology business from Thermo Fisher Scientific. The business will now operate as an independent company under the leadership of Chief Executive Officer Dirk Bontridder and will launch under a new corporate brand later in 2026. The Microbiology business is a global provider of diagnostic consumables and equipment used in microbiological testing across clinical, food safety, and pharmaceutical applications. The business serves more than 15,000 customers across over 100 countries and employs approximately 2,400 employees across 13 manufacturing and R&D sites around the world. Commenting on the completion, Judith Charpentier, Co-Managing Partner and Head of Healthcare at Astorg, said: "This is precisely the type of complex opportunity where Astorg can make a difference, combining deep healthcare expertise, an entrepreneurial and hands-on partnership model, and a strong track record of value creation across the companies we back." Olivier Lieven, Partner at Astorg, added: "We are delighted to welcome Dirk and look forward to working with him and the management team to deliver the company's next phase of growth, accelerate innovation and strengthen its global position." Dirk Bontridder, Chief Executive Officer, concluded: "This is a unique journey to create an independent global microbiology diagnostics company with an exceptional portfolio, talented teams and a long-standing reputation for quality, scientific excellence and customer service. I look forward to working with colleagues around the world and with Astorg to build on these strengths, continue delivering the products, service and innovation that our customers rely on, and introduce our new brand in due course as we begin this next chapter." Dirk brings more than 25 years of international leadership experience across life sciences, diagnostics and industrial technology. Most recently, he served as Chief Executive Officer of PerkinElmer, where he led the company's transformation into a focused global provider of analytical and laboratory solutions. He previously served as Chief Executive Officer of Reynaers Group and as Group Executive Vice President BioPharma Services & Clinical Diagnostics at Eurofins Scientific, one of the world's leading life sciences companies. Dirk began his career as a management consultant at McKinsey & Company. Story Continues About Astorg Astorg is a leading pan-European private equity firm with over €24 billion of assets under management. Astorg is a multi-specialist investor with deep expertise in healthcare, technology and business services. Within healthcare, Astorg concentrates on a narrow set of subsectors: pharmaceutical services and technology, MedTech and MedTech services, life science tools, and diagnostics. Enjoying a distinct entrepreneurial culture, an engaged shareholder perspective and a lean decision making body, Astorg works with founders, entrepreneurs and management teams to acquire premium international B2B businesses, providing them with strategic guidance, governance and capital to enhance their strategic positioning and achieve their financial objectives. Headquartered in Luxembourg, Astorg has offices in London, Paris, New York, Frankfurt, and Milan. For more information about Astorg:

Published

12 Aug 2026 13:10

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Company Logo Accelerating momentum across major industry heavyweights—highlighted by Thermo Fisher Scientific's Q2 2026 revenue beat, Hamamatsu Photonics' launch of its dedicated Lasers & Fibers Business Unit, and BD's $4.98 billion Q3 performance—is driving rapid adoption of optical diagnostic and imaging solutions worldwide. This report provides an in-depth analysis of key technological advancements, regional market shares, and competitive strategies across the global biophotonics sector. Biophotonics MarketBiophotonics Market Dublin, Aug. 12, 2026 (GLOBE NEWSWIRE) -- The "Biophotonics - A Global Market Overview" has been added to ResearchAndMarkets.com's offering. Global Biophotonics Market to Reach US$123 Billion by 2032, Driven by Advanced Imaging and Medical Diagnostics The global biophotonics market is projected to expand from US$70.4 billion in 2025 to US$123 billion by 2032, registering a compound annual growth rate (CAGR) of 8.3% during the forecast period. Growth is supported by the rising adoption of non-invasive diagnostic systems, increasing demand for precision medicine, advances in optical imaging, and broader use of light-based technologies across healthcare, life sciences, research, and industrial applications. Advanced imaging systems, molecular diagnostics, biosensors, and continued innovation in in-vivo and in-vitro technologies are among the primary factors strengthening the global biophotonics market outlook. Imaging remained the largest application segment in 2025, while medical diagnostics accounted for the leading share of end-use revenue. Non-medical applications are expected to deliver the fastest growth through 2032 as biophotonic technologies gain traction in environmental monitoring, agriculture, food analysis, and industrial testing. Regional Biophotonics Market Outlook North America led the global biophotonics market in 2025, accounting for 38.7% of total revenue. The region's leadership reflects its established healthcare infrastructure, substantial research and development activity, high adoption of advanced diagnostic technologies, and strong presence of leading market participants. Europe ranked as the second-largest regional market, supported by continued investment in medical research, optical technologies, and life sciences. Asia-Pacific is forecast to record the fastest regional growth, with a CAGR of 10% from 2025 to 2032. The regional market is projected to reach US$32.6 billion by 2032, representing 26.5% of global revenue. Expanding healthcare infrastructure, growing research investment, rising healthcare expenditure, and increasing adoption of advanced medical imaging and diagnostic platforms are expected to support this expansion. Story Continues Market Analysis by Application and Sub-Type Imaging was the largest biophotonics application segment in 2025, generating US$39 billion, followed by analytics and sensing. See-through imaging led the imaging category with revenue of US$16.6 billion. Surface imaging is projected to be the fastest-growing imaging sub-type, advancing at a CAGR of 9.3% through 2032. Within analytics and sensing, molecular spectroscopy held a dominant 64.3% share in 2025. Biosensors are forecast to be the fastest-growing sub-type as demand increases for rapid, sensitive, and minimally invasive testing across clinical diagnostics, pharmaceutical development, environmental analysis, and biological research. In processing and curing, light therapy accounted for 82.5% of segment revenue and is expected to retain its leading position during the forecast period. Market Analysis by Technology In-vivo technology was the leading segment in 2025, valued at US$39.5 billion and accounting for 56.2% of global biophotonics market revenue. The segment is also expected to post the fastest technology-based growth, registering a CAGR of 8.5% and reaching US$70 billion by 2032. Demand is being reinforced by advances in real-time imaging, disease detection, surgical guidance, phys

Published

12 Aug 2026 12:20

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Published

12 Aug 2026 09:05

Provider record

News feed

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The "Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market is projected to increase from USD 0.89 billion in 2026 to USD 2.01 billion by 2035, expanding at a compound annual growth rate of 9.5% during the forecast period. Market growth is being driven by rising demand for nucleic acid-based therapeutics, continued investment in cell and gene therapy research, and technological advances in intracellular delivery systems. Non-Viral Transfection Reagents Market Growth and Trends The expanding development and commercialization of gene therapies, mRNA therapeutics, RNA interference drugs, DNA vaccines, and gene-editing technologies are increasing demand for efficient transfection reagents and systems. Regulatory approvals for nucleic acid-based therapies have further reinforced the clinical and commercial potential of this therapeutic class. Industry stakeholders are increasingly adopting non-viral gene delivery technologies in response to the limitations associated with viral vectors, including immunogenicity, cytotoxicity, high manufacturing costs, restricted cargo capacity, and complex production requirements. Non-viral transfection platforms can offer greater scalability, manufacturing flexibility, and suitability for research and therapeutic workflows. Advances in lipid-based, polymer-based, nanoparticle-based, and electroporation systems are improving intracellular uptake, delivery precision, cell viability, and compatibility across diverse cell types. Nanotechnology-enabled carriers are also supporting targeted delivery through multifunctional designs that incorporate therapeutic payloads and targeting ligands. Products leveraging these technologies include jetOPTIMUS and PolyMag. Key Market Drivers and Challenges Major growth drivers include the increasing prevalence of chronic diseases, expanding pharmaceutical and biotechnology research expenditure, growing adoption of CRISPR-Cas9 and other gene-editing platforms, and rising demand for advanced cell and gene therapies. The need for scalable delivery technologies across research, process development, and clinical manufacturing is expected to create additional opportunities for non-viral transfection reagent developers. Despite a favorable outlook, the market faces challenges related to transfection efficiency in primary and hard-to-transfect cells. Limited intracellular uptake, genetic material stability, transient gene expression, reagent-related cytotoxicity, and variable performance across cell lines may also affect adoption. Additional barriers include the absence of standardized protocols, substantial optimization costs, regulatory complexity, and competition from emerging delivery platforms. Story Continues Market Segmentation Highlights The non-viral transfection reagents market is segmented by transfection method, application, end-user, and geography. Method: Chemical methods, physical methods, and other methods Application: Research applications and clinical applications End-user: Academic and research institutions, pharmaceutical and biotechnology companies, contract manufacturers, and other end-users Geography: North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa Chemical methods account for nearly 60% of the overall non-viral transfection reagents and equipment market. This position is supported by the broad adoption of chemical reagents and non-viral vectors in primary cell transfection and gene therapy research. Physical methods are expected to register a comparatively higher growth rate through 2035, supported by advances in electroporation technologies that can provide shorter processing times, lower toxicity, and broad compatibility with nucleic acid

Published

11 Aug 2026 09:45

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Published

10 Aug 2026 22:23

Provider record

snapshot

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 1%.In corporate news, Eli Lilly (LLY) received UK authorization for Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now

Published

10 Aug 2026 20:58

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index up 0.9% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

Published

10 Aug 2026 18:40

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Last Friday, the three major Wall Street indexes closed a winning week. The Nasdaq Composite, the S&P 500 and the Dow Jones Industrial Average gained 5.2%, 3.6% and 3%, respectively. Wall Street's strong weekly performance was driven by renewed investor optimism over the U.S. economic outlook, expectations for a supportive Federal Reserve policy environment and easing concerns about inflation. Strong corporate earnings also helped reinforce confidence in the market's growth prospects. Technology and growth-oriented sectors led the advance, boosting the Nasdaq, while broader participation supported gains in the S&P 500 and Dow. Falling Treasury yields and expectations of potential interest-rate cuts further encouraged investors to increase exposure to equities, lifting major indexes to stronger weekly finishes. Regardless of market conditions, we, here at Zacks, provide investors with unbiased guidance on how to beat the market. As usual, Zacks Research guided investors over the past three months with its time-tested methodologies. Given the prevailing market uncertainty, you may want to look at our feats to prepare better for your next action. Here are some of our key achievements: Aveanna and Surgery Partners Surge Following Zacks Rank Upgrade Shares of Aveanna Healthcare Holdings Inc. AVAH have gained 32.4% (versus the S&P 500's 2.2% increase) since it was upgraded to a Zacks Rank #2 (Buy) on June 1. Another stock, Surgery Partners, Inc. SGRY, which was upgraded to a Zacks Rank #1 (Strong Buy) on June 1, has returned 16.2% since then. A portfolio of Zacks # 1 Rank (Strong Buy) stocks has outperformed the S&P 500 index by 5.7 percentage points this year. Through July 6th this year, the Zacks # 1 Rank portfolio returned +15.3%, which compares to a +9.7% gain for the S&P 500 index and a +12.6% gain for the equal-weight version of the index in the same time period. Since its inception in 1988, this portfolio of Zacks # 1 Rank stocks has outperformed the market by 12.4 percentage points. The average annual return for this portfolio of Zacks # 1 Rank stocks since inception in 1988 was +23.9% through July 6th, which compared to a +11.6% gain for the S&P 500 index and a +11.4% gain for the equal-weight version of the index. You can see the complete list of today's Zacks Rank #1 stocks here >>> Check Aveanna's historical EPS and Sales here>>> Check Surgery Partner's historical EPS and Sales here>>>Zacks Investment Research Image Source: Zacks Investment Research Zacks Recommendation Upgrades TWFG and Heico Story Continues Shares of TWFG, Inc. TWFG and Heico Corporation HEI have surged 46.3% (versus the S&P 500's 4.8% rise) and 13.6% (versus the S&P 500's 4.6% rise), since their Zacks Recommendation was upgraded to Outperform on June 8 and June 9, respectively. While the Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon, the Zacks Recommendation aims to predict performance over the next 6 to 12 months. However, just like the Zacks Rank, the foundation for the Zacks Recommendation is trends in earnings estimate revisions. The Zacks Recommendation classifies stocks into three groups — Outperform, Neutral and Underperform. While these recommendations are determined quantitatively, our analysts have the flexibility to override them for the 1100+ stocks they closely follow based on their better judgment of factors such as valuation, industry conditions and management effectiveness than the quantitative model. To access our research reports with Zacks Recommendations for the 1100+ stocks we cover, click here>>> Zacks Focus List Stocks Shopify, CACI Shoot Up Shares of Shopify Inc. SHOP, which belongs to the Zacks Focus List, have gained 37.3% over the past 12 weeks. The stock was added to the Focus List on September 6, 2022. Another Focus-List holding, CACI International CACI, which was added to the list on December 2, 2015, has returned 34% over the past 12 weeks. The S&P 500 has

Published

10 Aug 2026 13:34

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

The Top 5 Analyst Questions From Thermo Fisher's Q2 Earnings Call Thermo Fisher's second quarter saw a notable uptick in end-market activity, propelling results above Wall Street's expectations and leading to a positive market reaction. Management pointed to stronger demand across pharmaceutical, biotech, industrial, and diagnostics markets, with CEO Marc Casper highlighting "broad-based momentum" and "excellent execution" in core segments such as Bioproduction and Clinical Research. Newly launched high-end instruments and AI-powered software were key contributors, helping the company capture

Published

30 Jul 2026 18:17

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

TMO Q2 Deep Dive: Broad-Based End Market Growth and Strategic Portfolio Moves Life sciences company Thermo Fisher (NYSE:TMO) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 10.5% year on year to $11.99 billion. Its non-GAAP profit of $6.03 per share was 5.6% above analysts' consensus estimates. Is now the time to buy TMO? Find out in our full research report (it's free). Thermo Fisher (TMO) Q2 CY2026 Highlights: Revenue: $11.99 billion vs analyst estimates of $11.72 billion (10.5% year-on-year growth, 2.4% beat) Adjusted EPS: $6.03 vs analyst estimates of $

Published

24 Jul 2026 15:09

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Thermo Fisher Scientific (TMO) reported $11.99 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 10.5%. EPS of $6.03 for the same period compares to $5.36 a year ago. The reported revenue represents a surprise of +2.67% over the Zacks Consensus Estimate of $11.68 billion. With the consensus EPS estimate being $5.71, the EPS surprise was +5.6%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics al

Published

23 Jul 2026 14:30

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated